Xiaona Jing

Title: Xiaona Jing - Innovator in Antibody-Drug Conjugate Formulations

Introduction

Xiaona Jing is a notable inventor based in Riehen, Switzerland. She has made significant contributions to the field of biopharmaceuticals, particularly in the development of antibody-drug conjugates (ADCs). Her innovative work focuses on creating formulations that enhance the efficacy and stability of these therapeutic agents.

Latest Patents

Xiaona Jing holds a patent for a formulation for antibody and drug conjugate thereof. This patent discloses surfactant-free antibody and ADC formulations for anti-AXL antibodies and ADCs. The formulations include aqueous formulations, lyophilized formulations, and reconstituted formulations, along with related processes and uses. These formulations are particularly suitable for an anti-AXL ADC based on an auristatin or DM1 derivative or other similarly hydrophobic drugs. Some of the formulations comprise histidine and mannitol, which contribute to their effectiveness.

Career Highlights

Xiaona Jing is currently employed at Genmab A/S, a leading biotechnology company specializing in the development of innovative antibody therapies. Her work at Genmab has positioned her as a key player in the advancement of ADC technology, which is crucial for targeted cancer therapies.

Collaborations

Xiaona collaborates with talented professionals in her field, including Timothy Warren Paul and Kelly Ann Roby. These collaborations enhance the research and development efforts at Genmab, fostering innovation and progress in biopharmaceuticals.

Conclusion

Xiaona Jing's contributions to the field of antibody-drug conjugates exemplify her commitment to advancing medical science. Her innovative formulations and collaborative efforts at Genmab A/S are paving the way for more effective cancer treatments.